Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 1.00 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 13/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22189861 | 0.87 | MKNK1 (0.77) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL16331591 | 0.83 | MKNK1 (0.71) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL1054031 | 0.83 | MKNK1 (0.71) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL3357770 | 0.83 | MKNK1 (0.71) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL16332724 | 0.79 | MKNK1 (0.65) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL31403778 | 0.77 | MKNK1 (0.62) | MKNK1KLK7DYRK1A | |
| SCHEMBL16331312 | 0.77 | MKNK1 (0.61) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL31403809 | 0.77 | MKNK1 (0.61) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL16331301 | 0.76 | MKNK1 (0.60) | MKNK1KLK7FYNDYRK1A | |
| SCHEMBL16332731 | 0.76 | MKNK1 (0.60) | MKNK1KLK7FYNDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650818-A | Casein kinase 1 inhibitors for the treatment of diseases associated with DUX4 expression such as muscular dystrophy and cancer | FACIO知识产权有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3982955-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2022-04-20 | — | — | EP | disclosed |
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | disclosed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-10 | — | — | US | disclosed |
| EP-2398802-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2385946-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND TUERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-8040450-B2 | Liquid crystal electro-optic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | disclosed |
| WO-2010070238-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| EP-2170889-A2 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZOÝ1,2-B¨PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016286-A2 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | MKNK1 200/4885KLK7 1311/4885FYN 610/4885 |
| US-20130012516-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | MKNK1 4318/4885KLK7 2332/4885FYN 1544/4885 |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | MKNK1 4318/4885KLK7 2332/4885FYN 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.